Seelos Forges Ahead With SLS-002, Says Primary Endpoint Miss Due To Underpowered Trial
The company blamed lack of funding for incomplete enrollment of the Phase II study in acute suicidal ideation and behavior in major depressive disorder, saying it would have reached statistical significance had it fully enrolled.
You may also be interested in...
The US FDA approved the esketamine nasal spray for adults with major depressive disorder with suicidal ideation or behavior, following its initial approval in 2019 for treatment-resistant depression.
The German drug maker is spending CHF450m to acquire T3, which is focused on developing live bacteria to treat cancers.
The drug maker will spend up to $610m to acquire Caraway, with a lead product candidate targeting TRPML1, a pathway implicated in a number of neurodegenerative diseases.